Symbols / XERS Stock $5.95 -1.49% Xeris Biopharma Holdings, Inc.

Healthcare • Biotechnology • United States • NMS
XERS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Stock Fundamentals
Scroll to Statements
Market Cap 1.03B Enterprise Value 1.19B Income 554.00K Sales 291.84M Book/sh 0.08 Cash/sh 0.64
Dividend Yield — Payout 0.00% Employees 435 IPO — P/E inf Forward P/E 16.74
PEG — P/S 3.52 P/B 72.56 P/C — EV/EBITDA 32.08 EV/Sales 4.07
Quick Ratio 1.48 Current Ratio 2.19 Debt/Eq 1885.44 LT Debt/Eq — EPS (ttm) 0.00 EPS next Y 0.36
EPS Growth — Revenue Growth 42.80% Earnings 2026-05-07 ROA 4.40% ROE — ROIC —
Gross Margin 85.41% Oper. Margin 19.55% Profit Margin 0.19% Shs Outstand 172.43M Shs Float 163.61M Short Float 9.88%
Short Ratio 7.80 Short Interest — 52W High 10.08 52W Low 4.13 Beta 0.99 Avg Volume 1.80M
Volume 1.13M Target Price $11.14 Recom Strong_buy Prev Close $6.04 Price $5.95 Change -1.49%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$11.14
Mean price target
2. Current target
$5.95
Latest analyst target
3. DCF / Fair value
$2.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.95
Low
$8.00
High
$18.00
Mean
$11.14

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-02 reit HC Wainwright & Co. Buy → Buy $10
2026-01-09 reit HC Wainwright & Co. Buy → Buy $10
2025-12-09 init Barclays — → Overweight $9
2025-11-07 main Oppenheimer Outperform → Outperform $18
2025-11-07 main HC Wainwright & Co. Buy → Buy $10
2025-11-07 main Piper Sandler Neutral → Neutral $8
2025-10-29 main Oppenheimer Outperform → Outperform $18
2025-09-17 main HC Wainwright & Co. Buy → Buy $10
2025-08-19 main Leerink Partners Outperform → Outperform $9
2025-08-08 main Craig-Hallum Buy → Buy $11
2025-08-08 main Oppenheimer Outperform → Outperform $8
2025-06-05 main Leerink Partners Outperform → Outperform $7
2025-05-09 main Oppenheimer Outperform → Outperform $7
2025-03-07 reit Piper Sandler Neutral → Neutral $4
2025-03-07 main Leerink Partners Outperform → Outperform $6
2025-03-07 main Craig-Hallum Buy → Buy $7
2025-03-07 reit HC Wainwright & Co. Buy → Buy $8
2025-01-29 reit Jefferies Buy → Buy $6
2024-11-11 main HC Wainwright & Co. Buy → Buy $7
2024-11-11 down Piper Sandler Overweight → Neutral $3
News
RSS: Latest XERS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 HECHT BETH P Officer — 16,667 $5.99 $99,859
2026-03-30 BRADY JAMES ALOYSIUS Director — 10,834 $5.54 $60,036
2026-03-12 MCCULLOCH KEVIN President — 48,898 $3.94 $199,992
2026-03-05 PIEPER STEVEN Chief Financial Officer — 41,927 $4.09 $197,308
2026-03-02 HECHT BETH P Officer — 16,667 $6.24 $104,086
2026-02-02 HECHT BETH P Officer — 16,667 $7.45 $124,147
2026-01-30 SHANNON JOHN PATRICK JR Chief Executive Officer — 478,436 $0.00 $0
2026-01-30 PIEPER STEVEN Chief Financial Officer — 154,986 $0.00 $0
2026-01-30 MCCULLOCH KEVIN President — 168,463 $0.00 $0
2026-01-30 NGUYEN ANH TU Officer — 121,293 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
291.85
+43.72%
203.07
+23.89%
163.91
+48.68%
110.25
Operating Revenue
291.85
+43.72%
203.07
+23.89%
163.91
+48.68%
110.25
Cost Of Revenue
42.57
+15.58%
36.83
+28.58%
28.64
+26.56%
22.63
Reconciled Cost Of Revenue
40.72
+16.17%
35.05
+33.13%
26.33
+26.52%
20.81
Gross Profit
249.28
+49.95%
166.24
+22.89%
135.27
+54.39%
87.61
Operating Expense
224.38
+12.26%
199.88
+11.49%
179.28
+5.74%
169.55
Research And Development
31.16
+21.93%
25.56
+14.41%
22.34
+6.56%
20.97
Selling General And Administration
182.37
+11.56%
163.48
+11.90%
146.09
+6.06%
137.75
Total Expenses
266.95
+12.77%
236.72
+13.85%
207.92
+8.19%
192.19
Operating Income
24.90
+173.99%
-33.65
+23.55%
-44.01
+46.29%
-81.94
Total Operating Income As Reported
24.90
+173.99%
-33.65
+23.55%
-44.01
+46.29%
-81.94
EBITDA
42.33
+402.49%
-13.99
+41.04%
-23.73
+65.76%
-69.31
Normalized EBITDA
42.33
+369.62%
-15.70
+39.84%
-26.10
+60.87%
-66.69
Reconciled Depreciation
12.69
+0.54%
12.62
-4.07%
13.16
+3.88%
12.67
EBIT
29.64
+211.34%
-26.62
+27.85%
-36.90
+55.00%
-81.98
Total Unusual Items
0.00
-100.00%
1.71
-27.83%
2.36
+190.23%
-2.62
Total Unusual Items Excluding Goodwill
0.00
-100.00%
1.71
-27.83%
2.36
+190.23%
-2.62
Special Income Charges
0.00
-100.00%
1.70
-28.14%
2.36
+153.95%
-4.38
Other Special Charges
—
2.69
-5.18%
2.84
+131.97%
1.22
Restructuring And Mergern Acquisition
0.00
+100.00%
-4.39
+15.62%
-5.20
-264.71%
3.16
Net Income
0.55
+101.01%
-54.84
+11.92%
-62.26
+34.23%
-94.66
Pretax Income
0.55
+100.97%
-57.10
+10.08%
-63.50
+33.91%
-96.08
Net Non Operating Interest Income Expense
-24.34
+3.27%
-25.16
-15.12%
-21.86
-89.67%
-11.52
Interest Expense Non Operating
29.08
-4.60%
30.48
+14.57%
26.61
+88.69%
14.10
Net Interest Income
-24.34
+3.27%
-25.16
-15.12%
-21.86
-89.67%
-11.52
Interest Expense
29.08
-4.60%
30.48
+14.57%
26.61
+88.69%
14.10
Interest Income Non Operating
4.74
-10.88%
5.32
+12.00%
4.75
+84.29%
2.58
Interest Income
4.74
-10.88%
5.32
+12.00%
4.75
+84.29%
2.58
Other Income Expense
—
1.71
-27.83%
2.36
+190.23%
-2.62
Gain On Sale Of Security
—
0.01
+700.00%
0.00
-99.94%
1.76
Tax Provision
0.00
+100.00%
-2.27
-81.59%
-1.25
+12.29%
-1.42
Tax Rate For Calcs
0.00
-100.00%
0.00
+101.94%
0.00
+32.71%
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
0.07
+45.73%
0.05
+219.74%
-0.04
Net Income Including Noncontrolling Interests
0.55
+101.01%
-54.84
+11.92%
-62.26
+34.23%
-94.66
Net Income From Continuing Operation Net Minority Interest
0.55
+101.01%
-54.84
+11.92%
-62.26
+34.23%
-94.66
Net Income From Continuing And Discontinued Operation
0.55
+101.01%
-54.84
+11.92%
-62.26
+34.23%
-94.66
Net Income Continuous Operations
0.55
+101.01%
-54.84
+11.92%
-62.26
+34.23%
-94.66
Normalized Income
0.55
+100.98%
-56.47
+12.54%
-64.57
+29.87%
-92.08
Net Income Common Stockholders
0.55
+101.01%
-54.84
+11.92%
-62.26
+34.23%
-94.66
Diluted EPS
0.00
+100.00%
-0.37
+17.78%
-0.45
+35.71%
-0.70
Basic EPS
0.00
+100.00%
-0.37
+17.78%
-0.45
+35.71%
-0.70
Basic Average Shares
160.43
+9.30%
146.77
+6.61%
137.67
+1.51%
135.63
Diluted Average Shares
172.74
+17.69%
146.77
+6.61%
137.67
+1.51%
135.63
Diluted NI Availto Com Stockholders
0.55
+101.01%
-54.84
+11.92%
-62.26
+34.23%
-94.66
Amortization
10.84
+0.00%
10.84
+0.00%
10.84
+0.00%
10.84
Amortization Of Intangibles Income Statement
10.84
+0.00%
10.84
+0.00%
10.84
+0.00%
10.84
Depreciation Amortization Depletion Income Statement
10.84
+0.00%
10.84
+0.00%
10.84
+0.00%
10.84
Depreciation And Amortization In Income Statement
10.84
+0.00%
10.84
+0.00%
10.84
+0.00%
10.84
Total Other Finance Cost
—
2.69
—
—
Line Item Trend 2023-12-31
Total Assets
322.60
Current Assets
156.26
Cash Cash Equivalents And Short Term Investments
72.45
Cash And Cash Equivalents
67.45
Other Short Term Investments
5.00
Receivables
39.20
Accounts Receivable
39.20
Inventory
38.84
Raw Materials
17.40
Work In Process
10.96
Finished Goods
10.47
Prepaid Assets
—
Other Current Assets
5.78
Total Non Current Assets
166.34
Net PPE
29.18
Gross PPE
35.21
Accumulated Depreciation
-6.04
Properties
0.00
Buildings And Improvements
23.20
Machinery Furniture Equipment
1.87
Other Properties
4.15
Leases
5.98
Goodwill And Other Intangible Assets
132.62
Goodwill
22.86
Other Intangible Assets
109.76
Other Non Current Assets
4.54
Total Liabilities Net Minority Interest
329.38
Current Liabilities
95.19
Payables And Accrued Expenses
40.27
Payables
11.56
Accounts Payable
11.56
Current Accrued Expenses
28.70
Pensionand Other Post Retirement Benefit Plans Current
16.96
Current Debt And Capital Lease Obligation
3.50
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
3.50
Other Current Liabilities
20.28
Total Non Current Liabilities Net Minority Interest
234.19
Long Term Debt And Capital Lease Obligation
225.70
Long Term Debt
190.93
Long Term Capital Lease Obligation
34.76
Non Current Deferred Liabilities
2.27
Non Current Deferred Taxes Liabilities
2.27
Other Non Current Liabilities
6.23
Stockholders Equity
-6.78
Common Stock Equity
-6.78
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
138.13
Ordinary Shares Number
138.13
Treasury Shares Number
0.00
Additional Paid In Capital
610.25
Retained Earnings
-617.02
Gains Losses Not Affecting Retained Earnings
-0.03
Other Equity Adjustments
-0.03
Total Equity Gross Minority Interest
-6.78
Total Capitalization
184.15
Working Capital
61.07
Invested Capital
184.15
Total Debt
229.19
Net Debt
123.48
Capital Lease Obligations
38.26
Net Tangible Assets
-139.41
Tangible Book Value
-139.41
Current Provisions
14.20
Interest Payable
1.37
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
28.63
+177.41%
-36.98
+21.36%
-47.02
+54.30%
-102.89
Cash Flow From Continuing Operating Activities
28.63
+177.41%
-36.98
+21.36%
-47.02
+54.30%
-102.89
Net Income From Continuing Operations
0.55
+101.01%
-54.84
+11.92%
-62.26
+34.23%
-94.66
Depreciation Amortization Depletion
12.69
+0.54%
12.62
-4.07%
13.16
+3.88%
12.67
Depreciation
1.85
+3.82%
1.78
-23.09%
2.32
+26.96%
1.82
Amortization Cash Flow
10.84
+0.00%
10.84
+0.00%
10.84
+0.00%
10.84
Depreciation And Amortization
12.69
+0.54%
12.62
-4.07%
13.16
+3.88%
12.67
Amortization Of Intangibles
10.84
+0.00%
10.84
+0.00%
10.84
+0.00%
10.84
Other Non Cash Items
3.37
+359.86%
-1.30
+51.48%
-2.67
-173.65%
3.63
Stock Based Compensation
22.37
+21.80%
18.36
+71.36%
10.72
-11.88%
12.16
Deferred Tax
0.00
+100.00%
-2.27
-81.59%
-1.25
+12.29%
-1.42
Deferred Income Tax
0.00
+100.00%
-2.27
-81.59%
-1.25
+12.29%
-1.42
Operating Gains Losses
—
0.08
-97.07%
2.84
+1042.52%
-0.30
Gain Loss On Investment Securities
—
-0.01
-700.00%
-0.00
+99.94%
-1.76
Gain Loss On Sale Of PPE
—
0.09
-71.65%
0.32
+36.02%
0.24
Change In Working Capital
-10.36
-17.46%
-8.82
-40.13%
-6.29
+82.09%
-35.15
Change In Receivables
-10.63
-773.15%
-1.22
+85.44%
-8.37
+37.44%
-13.37
Changes In Account Receivables
-10.63
-773.15%
-1.22
+85.44%
-8.37
+37.44%
-13.37
Change In Inventory
-19.29
-119.61%
-8.78
+40.68%
-14.80
-98.31%
-7.46
Change In Prepaid Assets
-2.10
-25.34%
-1.67
-152.18%
3.21
+182.48%
-3.89
Change In Payables And Accrued Expense
19.62
+1062.43%
-2.04
-131.69%
6.43
+146.21%
-13.93
Change In Accrued Expense
19.69
+160.01%
7.57
+1545.42%
-0.52
+94.55%
-9.61
Change In Payable
-0.07
+99.28%
-9.61
-238.14%
6.96
+261.16%
-4.32
Change In Account Payable
-0.07
+99.28%
-9.61
-238.14%
6.96
+261.16%
-4.32
Change In Other Working Capital
3.61
-5.30%
3.81
-40.60%
6.42
-33.70%
9.68
Change In Other Current Liabilities
-1.58
-245.93%
1.08
+32.03%
0.82
+113.24%
-6.18
Investing Cash Flow
-0.70
-114.25%
4.88
+181.33%
-6.00
-117.42%
34.46
Cash Flow From Continuing Investing Activities
-0.70
-114.25%
4.88
+181.33%
-6.00
-117.42%
34.46
Capital Expenditure
-0.70
+19.82%
-0.87
+61.64%
-2.26
-331.87%
-0.52
Capital Expenditure Reported
-0.70
+19.82%
-0.87
+61.64%
-2.26
-331.87%
-0.52
Net Investment Purchase And Sale
0.00
-100.00%
5.75
+253.73%
-3.74
-110.69%
34.98
Purchase Of Investment
0.00
+100.00%
-34.48
+21.16%
-43.74
0.00
Sale Of Investment
0.00
-100.00%
40.24
+0.59%
40.00
+14.33%
34.98
Net Business Purchase And Sale
—
—
0.00
0.00
Financing Cash Flow
11.39
-68.51%
36.17
+2342.28%
-1.61
-101.27%
127.47
Cash Flow From Continuing Financing Activities
11.39
-68.51%
36.17
+2342.28%
-1.61
-101.27%
127.47
Net Issuance Payments Of Debt
0.00
-100.00%
38.17
0.00
-100.00%
101.98
Issuance Of Debt
0.00
-100.00%
50.00
0.00
-100.00%
146.21
Repayment Of Debt
0.00
+100.00%
-11.83
0.00
+100.00%
-44.23
Long Term Debt Issuance
0.00
-100.00%
50.00
0.00
-100.00%
146.21
Long Term Debt Payments
0.00
+100.00%
-11.83
0.00
+100.00%
-44.23
Net Long Term Debt Issuance
0.00
-100.00%
38.17
0.00
-100.00%
101.98
Net Common Stock Issuance
-1.71
+54.23%
-3.73
-270.07%
-1.01
-103.42%
29.53
Common Stock Payments
-10.88
-191.27%
-3.73
-270.07%
-1.01
-115.60%
-0.47
Repurchase Of Capital Stock
-10.88
-191.27%
-3.73
-270.07%
-1.01
-115.60%
-0.47
Proceeds From Stock Option Exercised
13.10
+655.80%
1.73
+198.28%
0.58
-30.50%
0.84
Net Other Financing Charges
—
—
-1.19
+75.70%
-4.88
Changes In Cash
39.32
+866.07%
4.07
+107.45%
-54.64
-192.54%
59.04
Effect Of Exchange Rate Changes
—
—
0.00
0.00
Beginning Cash Position
75.74
+5.68%
71.67
-43.26%
126.31
+87.77%
67.27
End Cash Position
115.06
+51.91%
75.74
+5.68%
71.67
-43.26%
126.31
Free Cash Flow
27.93
+173.79%
-37.85
+23.21%
-49.29
+52.34%
-103.42
Interest Paid Supplemental Data
27.12
+0.64%
26.95
-2.67%
27.69
+154.96%
10.86
Amortization Of Securities
0.00
+100.00%
-0.75
+40.86%
-1.26
-786.41%
0.18
Common Stock Issuance
9.17
0.00
0.00
-100.00%
30.00
Issuance Of Capital Stock
9.17
0.00
0.00
-100.00%
30.00
Sale Of Business
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category